<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

2022 Medtech & Healthtech stage

Designed exclusively for medtech & healthtech companies.



Medtech Investment Dynamics - Pragmatic advice and optimism for 2023?

With a record-breaking benchmark set in 2021, are the slowing IPOs, M&As and a muted performance in SPACs an accurate portrayal of a seemingly quieter MedTech market? A panel of MedTech investors discuss how the current landscape will inform investment in 2023 and how MedTech companies can prepare for the year ahead.

  • How are macro factors (geopolitics, ESG, supply chain, inflation) influencing investment decisions, what does this mean for MedTech companies?
  • Are timelines for securing investment lengthening and, if so, why? How does this differ between early and late-stage funding, across Europe and the US?
  • With money becoming less of a commodity, what markets and device types are receiving attention from investors and how can companies build robust pitches to attract investment?

Moderator: Giles Hamilton, CEO, ODx Innovations
Joachim Rautter
, Managing Partner, Peppermint Venture Partners
Rebecca Todd
, Investment Director, Longwall Venture Partners
Vivien de Tusch-Lec
, General Partner, RYSE Asset Management

Giles Hamilton, CEO, ODx InnovationsJoachim Rautter, Managing Partner, Peppermint Venture Partners GmbH 300xRebecca Todd, Investment Director, Longwall Venture PartnersVivien de Tusch-Lec, General Partner, RYSE Asset Management

11:15 Locate Bio Logo


11:30 Fertiga Logo


11:45 Biofidelity Logo


12:00 Onward Medical Logo


12:15 ARC Medical Logo


12:30 Pixium Vision Logo


12:45 CeiROx Life Sciences Logo


13:00 Oxford Endovascular Logo


13:15 Harmonic Bionics Logo


13:30 Affluent Medical Logo


13:45 miDiagnostics 300x



Investment within Digital Health & Healthtech: Reviewing the success, growth and funding

  • Evaluating the year so far- How does early-stage investment compare to late-stage investment?
  • Have the regulatory advancements in Europe affected investment activity in the digital therapeutics and digital health space?
  • How do we make Europe a destination of choice for VC Start-up scale up?
  • Contrasting US and EU investment landscapes: Looking at the differences, US have higher valuations, raise a lot more capital. Why is that?
  • Are we now beyond the hype? The adoption of AI and machine learning in healthcare

Moderator: Tina Tan, Executive Editor, FirstWord HealthTech
Catherine Boule
, Managing Partner, Karista
Rabab Nasrallah, Investment Associate, Earlybird Health
Vijay Barathan
, Partner, Optum Ventures
Guillem Masferrer
, Investment Director, Asabys

Tina Tan, Executive Editor, FirstWord HealthTechCatherine Boule, Managing Partner, KaristaRabab Nasrallah, Investment Associate, Earlybird HealthVijay Barathan, Senior Principal, Optum Ventures 300xGuillem Masferrer, Investment Director, Asabys


Hy2care 300x



Cutiss AG Logo






Curesponse Logo



TechnoPulm Logo


16:00 Genetika+ Logo



Genefirst Logo



Butterfly Medical Logo



Kinetikos Health Logo



ImageBiopsyLab Logo



Close of Investival Showcase


Lifestars Logo

Awards & Gala Dinner
- Separate ticket required
- Find out more